Table 5 Logistic regression analyses predicting probability of prostate cancer in subjects with tPSA 4–10 ng/mL

Age

0.63

(0.51–0.74)

0.235

1.069

(1.01–1.13);

0.031

1.081

(1.02–1.15); 0.013

1.084

(1.01–1.16); 0.018

1.084

(1.01–1.16); 0.018

tPSA, ng/mL

0.50

(0.38–0.61) –

1.024

(0.76–1.38); 0.875

1.615

(0.66–3.86); 0.281

1.384

(0.49 − 3.88); 0.536

1.243

(0.44–3.48); 0.679

fPSA

0.59

(0.47–0.70) 0.418

0.529

(0.18–1.53); 0.240

0.038

(0.00–11.2); 0.261

0.070

(0.00–53.9); 0.433

0.071

(0.00–56.5); 0.437

%fPSA

0.63

(0.52–0.74) 0.090

0.961

(0.89–1.03); 0.284

1.155

(0.80–1.66); 0.448

1.108

(0.73–1.69); 0.631

1.108

(0.73–1.69); 0.632

p2PSA, pg/mL

0.59

(0.47–0.70) 0.286

1.023

(1.00–1.05); 0.089

–

–

–

%p2PSA

0.70

(0.59–0.81) 0.038

1.020

(1.00–1.04); 0.007

–

1.022

(1.01–1.04); 0.007

–

PHI

0.70

(0.59–0.81) 0.020

1.743

(1.19–2.56); 0.005

–

–

1.760

(1.17–2.64); 0.006

AUC of multivariate models (95% CI);

–

–

0.682

(0.57–0.78)

0.003

0.784

(0.68–0.87)

< 0.001

0.787

(0.68–0.87)

< 0.001

Gain in predictive accuracy (95% CI);

P value

–

–

–

0.102

(− 0.00–0.21);

0.054

0.104

(0.00–0.21);

0.048